Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer

John Merriman, Susan M. Sereika, Adam M. Brufsky, Priscilla F. McAuliffe, Kandace P. McGuire, Jamie S. Myers, Mary L. Phillips, Christopher M. Ryan, Amanda L. Gentry, Lindsay D. Jones, Catherine M. Bender

Research output: Contribution to journalArticle

Abstract

Objective: In a sample of 368 postmenopausal women, we (1) determined within-cohort and between-cohort relationships between adjuvant systemic therapy for breast cancer and self-reported cognitive function during the first 18 months of therapy and (2) evaluated the influence of co-occurring symptoms, neuropsychological function, and other covariates on relationships. Methods: We evaluated self-reported cognitive function, using the Patient Assessment of Own Functioning Inventory (PAOFI), and potential covariates (e.g., co-occurring symptom scores and neuropsychological function z-scores) in 158 women receiving aromatase inhibitor (AI) therapy alone, 104 women receiving chemotherapy followed by AI therapy, and 106 non-cancer controls. Patients were assessed before systemic therapy and then every 6 months, for a total of four assessments over 18 months. Controls were assessed at matched time points. Mixed-effects modeling was used to determine longitudinal relationships. Results: Controlling for covariates, patients enrolled before chemotherapy reported poorer global cognitive function (p < 0.001), memory (p < 0.001), language and communication (p < 0.001), and sensorimotor function (p = 0.002) after chemotherapy. These patients reported poorer higher-level cognitive and intellectual functions from before chemotherapy to 12 months after initiation of AI therapy (p < 0.001). Higher levels of depressive symptoms (p < 0.001), anxiety (p < 0.001), and fatigue (p = 0.040) at enrollment were predictors of poorer cognitive function over time. PAOFI total score was a predictor of executive function (p = 0.048) and visual working memory (p = 0.005) z-scores, controlling for covariates. Conclusions: Findings provide further evidence of poorer self-reported cognitive function after chemotherapy and of relationships between co-occurring symptoms and cognitive changes. AI therapy alone does not have an impact on self-reported cognitive function.

Original languageEnglish (US)
Pages (from-to)44-52
Number of pages9
JournalPsycho-Oncology
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Cognition
Aromatase Inhibitors
Breast Neoplasms
Drug Therapy
Therapeutics
Equipment and Supplies
Neurobehavioral Manifestations
Executive Function
Short-Term Memory
Fatigue
Language
Anxiety
Communication
Depression

ASJC Scopus subject areas

  • Experimental and Cognitive Psychology
  • Oncology
  • Psychiatry and Mental health

Cite this

Merriman, J., Sereika, S. M., Brufsky, A. M., McAuliffe, P. F., McGuire, K. P., Myers, J. S., ... Bender, C. M. (2017). Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. Psycho-Oncology, 26(1), 44-52. https://doi.org/10.1002/pon.4009

Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. / Merriman, John; Sereika, Susan M.; Brufsky, Adam M.; McAuliffe, Priscilla F.; McGuire, Kandace P.; Myers, Jamie S.; Phillips, Mary L.; Ryan, Christopher M.; Gentry, Amanda L.; Jones, Lindsay D.; Bender, Catherine M.

In: Psycho-Oncology, Vol. 26, No. 1, 01.01.2017, p. 44-52.

Research output: Contribution to journalArticle

Merriman, J, Sereika, SM, Brufsky, AM, McAuliffe, PF, McGuire, KP, Myers, JS, Phillips, ML, Ryan, CM, Gentry, AL, Jones, LD & Bender, CM 2017, 'Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer', Psycho-Oncology, vol. 26, no. 1, pp. 44-52. https://doi.org/10.1002/pon.4009
Merriman, John ; Sereika, Susan M. ; Brufsky, Adam M. ; McAuliffe, Priscilla F. ; McGuire, Kandace P. ; Myers, Jamie S. ; Phillips, Mary L. ; Ryan, Christopher M. ; Gentry, Amanda L. ; Jones, Lindsay D. ; Bender, Catherine M. / Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. In: Psycho-Oncology. 2017 ; Vol. 26, No. 1. pp. 44-52.
@article{f36e5b61b93f4f509381f0048db28b03,
title = "Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer",
abstract = "Objective: In a sample of 368 postmenopausal women, we (1) determined within-cohort and between-cohort relationships between adjuvant systemic therapy for breast cancer and self-reported cognitive function during the first 18 months of therapy and (2) evaluated the influence of co-occurring symptoms, neuropsychological function, and other covariates on relationships. Methods: We evaluated self-reported cognitive function, using the Patient Assessment of Own Functioning Inventory (PAOFI), and potential covariates (e.g., co-occurring symptom scores and neuropsychological function z-scores) in 158 women receiving aromatase inhibitor (AI) therapy alone, 104 women receiving chemotherapy followed by AI therapy, and 106 non-cancer controls. Patients were assessed before systemic therapy and then every 6 months, for a total of four assessments over 18 months. Controls were assessed at matched time points. Mixed-effects modeling was used to determine longitudinal relationships. Results: Controlling for covariates, patients enrolled before chemotherapy reported poorer global cognitive function (p < 0.001), memory (p < 0.001), language and communication (p < 0.001), and sensorimotor function (p = 0.002) after chemotherapy. These patients reported poorer higher-level cognitive and intellectual functions from before chemotherapy to 12 months after initiation of AI therapy (p < 0.001). Higher levels of depressive symptoms (p < 0.001), anxiety (p < 0.001), and fatigue (p = 0.040) at enrollment were predictors of poorer cognitive function over time. PAOFI total score was a predictor of executive function (p = 0.048) and visual working memory (p = 0.005) z-scores, controlling for covariates. Conclusions: Findings provide further evidence of poorer self-reported cognitive function after chemotherapy and of relationships between co-occurring symptoms and cognitive changes. AI therapy alone does not have an impact on self-reported cognitive function.",
author = "John Merriman and Sereika, {Susan M.} and Brufsky, {Adam M.} and McAuliffe, {Priscilla F.} and McGuire, {Kandace P.} and Myers, {Jamie S.} and Phillips, {Mary L.} and Ryan, {Christopher M.} and Gentry, {Amanda L.} and Jones, {Lindsay D.} and Bender, {Catherine M.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/pon.4009",
language = "English (US)",
volume = "26",
pages = "44--52",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer

AU - Merriman, John

AU - Sereika, Susan M.

AU - Brufsky, Adam M.

AU - McAuliffe, Priscilla F.

AU - McGuire, Kandace P.

AU - Myers, Jamie S.

AU - Phillips, Mary L.

AU - Ryan, Christopher M.

AU - Gentry, Amanda L.

AU - Jones, Lindsay D.

AU - Bender, Catherine M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: In a sample of 368 postmenopausal women, we (1) determined within-cohort and between-cohort relationships between adjuvant systemic therapy for breast cancer and self-reported cognitive function during the first 18 months of therapy and (2) evaluated the influence of co-occurring symptoms, neuropsychological function, and other covariates on relationships. Methods: We evaluated self-reported cognitive function, using the Patient Assessment of Own Functioning Inventory (PAOFI), and potential covariates (e.g., co-occurring symptom scores and neuropsychological function z-scores) in 158 women receiving aromatase inhibitor (AI) therapy alone, 104 women receiving chemotherapy followed by AI therapy, and 106 non-cancer controls. Patients were assessed before systemic therapy and then every 6 months, for a total of four assessments over 18 months. Controls were assessed at matched time points. Mixed-effects modeling was used to determine longitudinal relationships. Results: Controlling for covariates, patients enrolled before chemotherapy reported poorer global cognitive function (p < 0.001), memory (p < 0.001), language and communication (p < 0.001), and sensorimotor function (p = 0.002) after chemotherapy. These patients reported poorer higher-level cognitive and intellectual functions from before chemotherapy to 12 months after initiation of AI therapy (p < 0.001). Higher levels of depressive symptoms (p < 0.001), anxiety (p < 0.001), and fatigue (p = 0.040) at enrollment were predictors of poorer cognitive function over time. PAOFI total score was a predictor of executive function (p = 0.048) and visual working memory (p = 0.005) z-scores, controlling for covariates. Conclusions: Findings provide further evidence of poorer self-reported cognitive function after chemotherapy and of relationships between co-occurring symptoms and cognitive changes. AI therapy alone does not have an impact on self-reported cognitive function.

AB - Objective: In a sample of 368 postmenopausal women, we (1) determined within-cohort and between-cohort relationships between adjuvant systemic therapy for breast cancer and self-reported cognitive function during the first 18 months of therapy and (2) evaluated the influence of co-occurring symptoms, neuropsychological function, and other covariates on relationships. Methods: We evaluated self-reported cognitive function, using the Patient Assessment of Own Functioning Inventory (PAOFI), and potential covariates (e.g., co-occurring symptom scores and neuropsychological function z-scores) in 158 women receiving aromatase inhibitor (AI) therapy alone, 104 women receiving chemotherapy followed by AI therapy, and 106 non-cancer controls. Patients were assessed before systemic therapy and then every 6 months, for a total of four assessments over 18 months. Controls were assessed at matched time points. Mixed-effects modeling was used to determine longitudinal relationships. Results: Controlling for covariates, patients enrolled before chemotherapy reported poorer global cognitive function (p < 0.001), memory (p < 0.001), language and communication (p < 0.001), and sensorimotor function (p = 0.002) after chemotherapy. These patients reported poorer higher-level cognitive and intellectual functions from before chemotherapy to 12 months after initiation of AI therapy (p < 0.001). Higher levels of depressive symptoms (p < 0.001), anxiety (p < 0.001), and fatigue (p = 0.040) at enrollment were predictors of poorer cognitive function over time. PAOFI total score was a predictor of executive function (p = 0.048) and visual working memory (p = 0.005) z-scores, controlling for covariates. Conclusions: Findings provide further evidence of poorer self-reported cognitive function after chemotherapy and of relationships between co-occurring symptoms and cognitive changes. AI therapy alone does not have an impact on self-reported cognitive function.

UR - http://www.scopus.com/inward/record.url?scp=84950115422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950115422&partnerID=8YFLogxK

U2 - 10.1002/pon.4009

DO - 10.1002/pon.4009

M3 - Article

C2 - 26486371

AN - SCOPUS:84950115422

VL - 26

SP - 44

EP - 52

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 1

ER -